Please login to the form below

Not currently logged in
Email:
Password:

Trophos

This page shows the latest Trophos news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

Latest news

  • Roche buys rare disease firm Trophos in €470m deal Roche buys rare disease firm Trophos in €470m deal

    Roche buys rare disease firm Trophos in 470m deal. Will take control of olesoxime for spinal muscular atrophy. ... Roche is paying 120m upfront for Marseilles-based Trophos, with another 350m promised in the form of milestone payments.

  • Christine Placet appointed CEO of Trophos

    Trophos has promoted its chief financial officer Christine Placet to CEO, replacing Damian Marron. ... Prior to joining Trophos in 2004, Placet served as chief financial officer in several companies across various industries.

  • Actelion net revenue up 18 per cent for Q2

    Actelion also confirmed it has obtained the option to purchase Trophos, a France-based clinical stage pharmaceutical company, for 10m. ... Trophos has a pipeline of new molecular entities in development for the motor neuron diseases amyotrophic lateral

  • Trophos SA Awarded $1.4mn research grant

    Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development. ... Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.

  • Pharma deals during January 2015 Pharma deals during January 2015

    A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics